瑞替普酶与尿激酶溶栓治疗中危肺栓塞的临床疗效

摘要

目的：对比分析瑞替普酶与尿激酶溶栓治疗中危组肺栓塞临床疗效。方法根据不同的治疗方案将所有患者分成瑞替普酶组(23例)与尿激酶组(39例),将两组患者溶栓效果进行对比与分析。结果治疗后两组D-二聚体、肌钙蛋白T、N-ProBNP及PASP均较治疗前降低(P<0．05),PaO2较治疗前升高(P<0．05),两组患者治疗前与治疗后24小时D-二聚体及肌钙蛋白T差值无明显区别(P>0．05),但瑞替普酶组PaO2、N-ProBNP、PASP治疗前后差值明显大于尿激酶组(P<0．05)。结论瑞替普酶及尿激酶均可以用于治疗急性中危组PTE,但于住院期间给予中危组肺栓塞患者,瑞替普酶溶栓治疗效果优于尿激酶。%Objective To compare the efficacy of reteplase and urokinase in the treatment of medium-risk pulmonary thromboembolism ( PET ) . Methods 62 patients with medium-risk pulmonary thromboembolism were divided into two groups to be treated with reteplase (23 cases) and urokinase (39 cases). The effect of thrombolysis was compared. Results The levels of D-dimer, troponin T, NT-ProBNP, and PASP decreased (P<0. 05), and the level of PaO2 increased in both groups after the treatment (P<0. 05), but the difference was more pronounced in the reteplase group than in the urokinase group (P<0. 05). There was no significant difference in D-dimer and troponin T between the two groups before and 24-hour after the treatment (P>0. 05). Conclusion Both reteplase and uroki-nase are safe and effective in the treatment of acute medium-risk PTE, but the curative effect of reteplase is superior to urokinase.